ReviewPsychopharmacology2025
The orexin/hypocretin system in dementia-related neurological disorders: a double-edged sword in cognitive impairment.
Review in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exercise-induced neuropeptidergic and neurochemical neuroadaptation in stress regulation and emotional disorders.Acta neurologica Belgica · 2026Review
- The NLRP3 Inflammasome in Neuropsychiatric Disorders: Molecular Mechanisms and Emerging Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Narcolepsy: immunity, neural circuitry, and brain network reconfiguration.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
rationaleThe orexin (OX) system plays a crucial role in regulating cognitive functions. Dysregulation of this system has been implicated in several dementia-related neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and dementia with Lewy bodies (DLB).
objectivesThis review aims to synthesize current research on the involvement of the OX system in dementia-related neurological diseases, focusing on its effects on cognitive function and its potential as a therapeutic target.
resultsThe OX system, encompassing hypothalamic neuropeptides and receptors (OX1R and OX2R), exhibits dysregulation in neurodegenerative diseases associated with dementia. Changes in OX concentrations strongly correlate with cognitive decline, and this correlation varies with disease progression. OX regulates essential molecular mechanisms, including neuronal survival, synaptic plasticity, neural network integrity, and circadian rhythm stability-processes impaired as cognitive deficits intensify. These findings emphasize OX's critical and context-dependent role in cellular resilience and cognitive function.
conclusionsOX system emerges as a multifaceted therapeutic target for dementia-related cognitive impairment. Its effects vary across disease stages, initially offering neuroprotection but later contributing to pathology. Moreover, OX's involvement in circadian rhythm regulation complicates its clinical utility, as disruptions exacerbate cognitive deficits. These opposing functions highlight the need for tailored, stage-specific interventions to maximize cognitive benefits while minimizing adverse signaling.
Indexed as
Identifiers
40522408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.